18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR

Gestational Pharmacokinetics: ADME Adaptations

Pregnancy triggers profound physiological adaptations altering drug Absorption, Distribution, Metabolism, and Elimination (ADME). Understanding these changes is critical to maintaining efficacy and preventing maternal-fetal toxicity.

1. Absorption & Bioavailability

• Gastrointestinal Motility: Elevated progesterone relaxes gastrointestinal smooth muscle, significantly prolonging gastric emptying and small-intestinal transit time by 30% to 50%. While total drug exposure (Area Under the Curve, AUC) is often preserved, peak serum concentration ($C_{\text{max}}$) is delayed or blunted.
• Gastric Acidity & Emesis: Gastric acid secretion declines while mucus secretion rises, elevating gastric pH and altering the ionization and dissolution of weakly acidic drugs. Hyperemesis gravidarum causes erratic retention and subtherapeutic levels.

2. Distribution & Protein Binding

• Fluid Expansion: Maternal plasma volume expands by 40% to 50% (~1,200 to 1,500 mL) alongside a 6 to 8 liter expansion in total body water. This expands the Volume of Distribution ($V_d$) for hydrophilic drugs (beta-lactams, aminoglycosides, lithium), lowering peak serum levels and requiring higher loading or maintenance doses.
• Adipose Accumulation: Maternal fat increases by 3 to 4 kg, expanding $V_d$ for lipophilic drugs (anesthetics, sedatives, psychotropics) and prolonging elimination half-lives ($t_{1/2}$).
• Hypoalbuminemia & Unbound Fraction: Serum albumin falls by 20% to 30% (from ~4.0 to ~3.0 g/dL) due to hemodilution. For highly protein-bound medications (>90%, such as phenytoin, valproic acid, carbamazepine, and diazepam), reduced binding capacity substantially increases the unbound, pharmacologically active ('free') drug fraction.

3. Hepatic Metabolism & Cytochrome P450 Enzymes

Elevated estrogen and progesterone alter hepatic Cytochrome P450 (CYP) and Phase II enzymes:

• Upregulated Enzymes: CYP3A4 activity accelerates clearance of calcium channel blockers, protease inhibitors, and corticosteroids. CYP2D6 activity accelerates clearance of SSRIs (fluoxetine, sertraline) and beta-blockers, often requiring dose increases in the 2nd and 3rd trimesters. CYP2C9 clears phenytoin more rapidly. Estrogen dramatically upregulates UGT1A4: lamotrigine clearance increases by up to 200% to 300%, dropping serum concentrations by 50% to 70% and triggering breakthrough seizures unless monthly levels are monitored and doses titrated.
• Downregulated Enzymes: CYP1A2 activity declines by ~50%, prolonging the half-life of caffeine (from 3–5 hours to 10–18 hours in late pregnancy) and theophylline. CYP2C19 metabolism of proton pump inhibitors also declines.

4. Renal Elimination & GFR

Renal blood flow increases by 50% to 80%, and Glomerular Filtration Rate (GFR) rises by 50% beginning in early gestation. Normal pregnancy baseline serum creatinine drops to 0.4 to 0.6 mg/dL (levels ≥0.8 mg/dL flag impairment). Renally eliminated drugs (penicillins, cephalosporins, low-molecular-weight heparins, lithium, digoxin) clear rapidly, requiring larger doses or shortened dosing intervals (e.g., every 8 hours instead of 12 hours).

---

The FDA Pregnancy & Lactation Labeling Rule (PLLR)

In June 2015, the FDA instituted the PLLR, eliminating the historical letter-category system (A, B, C, D, X). Letter categories were overly simplistic, frequently misread as a safety ranking, and assigned over 65% of prescription drugs to Category C (grouping drugs with proven animal teratogenicity with those lacking data). The letter system also omitted lactation and failed to convey risks across trimesters.

The Three Narrative PLLR Subsections (Labeling Section 8)

1. 8.1 Pregnancy (includes Labor and Delivery):
   • Pregnancy Exposure Registry: Contact details and web links for registries collecting prospective clinical data.
   • Risk Summary: Detailed narrative synthesizing human and animal data against the background baseline risk in the U.S. general population (2% to 4% for major congenital malformations, 15% to 20% for miscarriage).
   • Clinical Considerations: Outlines risks of untreated maternal disease, required gestational dose adjustments, maternal/fetal/neonatal adverse reactions, and labor/delivery management.
   • Data: Narrative review of human study cohorts and animal toxicology exposure margins.
2. 8.2 Lactation (includes Nursing Mothers):
   • Risk Summary: Identifies drug presence in human milk, estimated daily infant dose, and the Relative Infant Dose (RID).
   • Clinical Considerations: Outlines potential adverse effects in the nursing infant requiring monitoring, effects on milk production, and timing strategies to minimize exposure.
   • Data: Overview of published clinical lactation studies and infant drug levels.
3. 8.3 Females and Males of Reproductive Potential:
   • Outlines requirements for baseline pregnancy testing, contraception protocols (including duration and washout periods), and drug-induced reversible or irreversible effects on fertility.

---

Teratogenic Drug Classes, Critical Windows & Syndromes

Teratogenic susceptibility varies by gestational timing: the pre-differentiation "all-or-none" period (weeks 1–2 post-conception; lethal vs. complete recovery), embryonic organogenesis (weeks 3–8 post-conception; major structural malformations), and the fetal period (week 9 to term; growth restriction, functional deficits, or fetopathy).